Csl Ltd has released a press release.
CSL partners on new coagulation treatment
Filed with ASX ·
Watch CSL's latest callCSL (ASX:CSL) Q4 2026 Earnings Call · Replay · Aug 18Read the transcript of CSL (ASX:CSL) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from CSL
- CSL FY25 Results and Major Strategic Initiatives
- CSL Results Presentation
- CSL Statutory Accounts for FY2025
- Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
- Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
Later from CSL
- VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
- CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
- CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
- CSL near-term emissions reduction targets validated by the SBTi
- CSL: Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025
Follow CSL into a list and get an email when it puts out news.
Follow CSL